PubMed Health⌕ Search

Biomedical subjects

R M Parvin

Publications and source records attributed to R M Parvin.

4 recordsLinked to original sources
PubMed1990

Calibration and control in haemoglobinometry.

In assigning values to fresh blood specimens used for calibrating automated blood cell analysers, haemoglobin concentration should be determined by the ICSH recommended hemiglobincyanide (HiCN) method. Errors in the reference method may be caused by inadequate blood collection, e.g. incorrect anticoagulation; inadequate dilution, e.g. use of inadequately calibrated pipettes; incomplete conversion of haemoglobins to HiCN, e.g. insufficient time for reactions to come to completion; during measurement, e.g. due to turbidity of the HiCN solution to be measured; or by transcription error. Readily available commercial reagent systems and secondary standards are compared with ICSH standards as to their compliance with these standards.

Calibration↗
PubMed1984

Freeze/thaw stability of transferrin, and reference values obtained with kinetic nephelometry.

To determine whether transferrin is stable to repeated freezing and thawing, we used blood specimens from 100 normal adults. Their transferrin concentrations were determined by a laser kinetic nephelometric immunoassay. The sera were stored at 4 degrees C and analyzed the next day (day 1). Specimens 1-25 were stored at -20 degrees C and assayed again on days 3, 4, 8, 16, 22, and 43. Specimens 26-100 were stored at 4 degrees C and analyzed again on day 2. Transferrin proved to be stable to repeated freezing and thawing. Normal reference values with respect to sex and age are given, as determined with the Baker 420 Immunological Nephelometer.

Adult↗
PubMedDate not supplied

Immunobiologics and drugs available from the Centers for Disease Control.

The CDC provides to the medical profession various drugs and immunobiological materials, many of which are investigational. The products available at CDC have changed over the years to meet the changing needs of the American public. Availability of the investigational drugs and immunobiologics permits treatment of patients with diseases against which no FDA-approved drug or treatment is effective and permits research and development of new drugs by manufacturers.

Centers for Disease Control and Prevention, U.S.↗